UnitedHealth Group
NASDAQ: UNHKey stats
Price chart
About UnitedHealth Group
Health Care
Company profile
- IPO date
- Oct 17, 1984
- Website
- www.unitedhealthgroup.com
Healthcare peers
How UNH compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 LLY Eli Lilly and Company | $1004.92 | -0.18% | $946.37B | 37.44 |
 JNJ Johnson & Johnson | $226.71 | -1.77% | $549.56B | 26.34 |
 ABBV AbbVie Inc. | $210.39 | -0.18% | $371.72B | 87.96 |
 MRK Merck & Co. | $111.38 | -1.79% | $275.09B | 30.79 |
 PFE Pfizer Inc. | $25.33 | -1.63% | $144.17B | 19.57 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
UnitedHealth Group has a significant competitive advantage due to its integrated healthcare and insurance services. Its subsidiary Optum is a growth engine, leveraging data analytics and pharmacy benefits management to drive efficiencies. The company's sheer scale and market cap of $276.23 billion provide a robust moat against smaller competitors and new entrants. The health insurance sector frequently benefits from steady, recurring revenue streams, making UNH well-positioned even during economic downturns. Its current dividend yield of 2.8657% is appealing for income-focused investors seeking stability in their portfolios. Additionally, a P/E ratio of 22.91 suggests the stock is priced for growth, but not excessively so, leaving room for price appreciation if the company can continue to capitalize on the expanding healthcare market. The low beta of 0.425 indicates less volatility compared to the broader market, a plus for conservative investors.
Bear case
UNH faces significant risks from regulatory changes in healthcare policies, which could impact profit margins if reforms are unfavorable. Price trends are currently bearish, which may suggest underlying investor concerns about short-term performance. Competition remains fierce within the healthcare space, with numerous companies vying for market share through aggressive pricing and innovations. Companies like Anthem and Cigna pose constant competitive threats, which could limit UNH's ability to raise prices. The P/E ratio of 22.91 could be deemed high if earnings growth does not keep up with market expectations, leading to potential valuation corrections. Moreover, regulatory pressures could lead to increased costs, squeezing margins further.
Who should buy UNH
Long-term dividend investors who prioritize stability and are comfortable with gradual growth should consider UNH. It’s well-suited for those seeking exposure to the healthcare sector with a relatively lower risk profile due to its significant market cap and established position. However, investors must be willing to weather short-term market fluctuations and regulatory risks.
Key risks
- Regulatory changes that alter the landscape of health insurance and increase costs. - Rising competition from other healthcare insurers reducing pricing power. - Economic downturns impacting the profitability of employer-sponsored plans. - Potential valuation corrections if earnings do not meet investor expectations.
Where to buy UNH
Open an account with a broker we've reviewed and start trading UnitedHealth Group today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent UNH news
The Schwab US Dividend Equity ETF has moved sideways in the past few weeks, underperforming the broader market.
Berkshire Hathaway's equity portfolio got one of its biggest renovations ever during Greg Abel's first three months as the company's CEO.
Berkshire Hathaway has fully exited its position in UnitedHealth Group (NYSE:UNH) under Greg Abel's leadership. The sale removes a high profile institutional investor from UnitedHealth's shareholder base. The move is separate from recent earnings, guidance, or valuation developments for UnitedHealth Group. For investors watching UnitedHealth Group at a current share price of $393.85, Berkshire Hathaway's exit comes after a period of strong recent stock performance. NYSE:UNH is up 3.7% over...
Berkshire Hathaway added stakes in Delta and Macy's during Greg Abel's first quarter as CEO of the conglomerate, while eliminating holdings in Amazon and other major companies.
Berkshire Hathaway boosted its stake in Alphabet to nearly 58 million shares on March 31 from almost 18 million shares at year-end.
Berkshire Hathawayâs Q1 2026 13F: portfolio shrank to $263B, bigger Alphabet stake, Chevron cut, and exits from AMZN/DPZ/UNHâread more.
Presenter SpeechKevin Fischbeck All right. Great. It's my pleasure to be kicking off the healthcare conference with UnitedHealth Group. With us today, we have Wayne DeVeydt, who's the CFO of the...
UnitedHealth Group Incorporated (UNH) Bank of America Global Healthcare Conference 2026 May 11, 2026 8:00 PM EDTCompany ParticipantsWayne DeVeydt - Chief...
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.